Close

Merck (MRK) Stock Gains on Beat-and-Raise, Sees Up To $7 Billion in Sales of COVID-19 Drug, Analysts Bullish

Go back to Merck (MRK) Stock Gains on Beat-and-Raise, Sees Up To $7 Billion in Sales of COVID-19 Drug, Analysts Bullish

Merck Announces Third-Quarter 2021 Financial Results

October 28, 2021 6:30 AM EDT

Results Demonstrate Strong Momentum Across Business Third-Quarter 2021 Worldwide Sales Were $13.2 Billion, 20% Above Third-Quarter 2020; Excluding the Impact from Foreign Exchange, Sales Grew 19% Reflecting Strong Demand for the Companys Robust Portfolio: KEYTRUDA Sales Grew 22% to $4.5 Billion; Excluding the Impact from Foreign Exchange, Sales Grew 21% GARDASIL/GARDASIL 9 Sales Grew 68% to $2.0 Billion; Excluding the Impact from Foreign Exchange, Sales Grew 63% Animal Health Sales Grew 16% to $1.4 Billion; Excluding the Impact from Foreign Exchange, Sales Grew 14% Third-Quarter 2021 GAAP EPS from Continuing Operations Was $1.80; Third-Quarter 2021 Non-GAAP EPS from Continuing Operations Was $1.75 Bolstered Innovation... More